SC
NKTR icon

SummitTX Capital’s Nektar Therapeutics NKTR Stock Holding History

SummitTX Capital’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.07M Buy
42,624
+11,271
+36% +$642K 0.1% 232
2025
Q4 		$1.33M Buy
31,353
+24,555
+361% +$1.37M 0.04% 368
2025
Q3 		$387K Sell
6,798
-5,628
-45% -$186K 0.02% 577
2025
Q2 		$321K Buy
+12,426
New +$140K 0.01% 599

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

SummitTX Capital's NKTR Position: Q1 2026 in Review

SummitTX Capital increased its Nektar Therapeutics (NKTR) stake by 36% in Q1 2026, buying an estimated $642K and bringing the position to 42,624 shares worth $3.07M. The position accounts for 0.1% of the portfolio, ranked #232.

SummitTX Capital first reported a position in NKTR in Q2 2025 and has held it in 4 quarters since. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • SummitTX Capital held 42,624 shares of Nektar Therapeutics worth $3.07M as of Q1 2026.
  • SummitTX Capital bought 11,271 Nektar Therapeutics shares in Q1 2026, an estimated $642K.
  • Nektar Therapeutics made up 0.1% of SummitTX Capital's portfolio in Q1 2026, its #232 holding.
  • SummitTX Capital first reported a position in Nektar Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on SummitTX Capital's 13F filing for Q1 2026, filed 15 May 2026.